6 results on '"Yera Cobo, M."'
Search Results
2. Alterations of haemostasis in strenous physical activity: A case study | Alteraciones de la hemostasia en ejercicio de alta intensidad. A propósito de un caso
- Author
-
Carranza Márquez, M. D., Yera Cobo, M., Torres, B. C., Sarabia Cachadiña, E., Ribas Serna, J., and José Naranjo Orellana
3. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
- Author
-
Jiménez-Bárcenas R, García-Donas-Gabaldón G, Campos-Álvarez RM, Fernández-Sánchez de Mora MC, Luis-Navarro J, Domínguez-Rodríguez JF, Nieto-Hernández MDM, Sánchez-Bazán I, Yera-Cobo M, Cardesa-Cabrera R, Jiménez-Gonzalo FJ, Ruiz-Cobo MA, Caparrós-Miranda I, Entrena-Ureña L, Fernández Jiménez D, Díaz-Canales D, Moreno-Carrasco G, Calderón-Cabrera C, Núñez-Vázquez RJ, Pedrote-Amador B, and Mingot-Castellano ME
- Subjects
- Humans, Middle Aged, Female, Male, Spain, Aged, Retrospective Studies, Adult, Oxazines therapeutic use, Oxazines adverse effects, Pyrimidines therapeutic use, Pyrimidines adverse effects, Treatment Outcome, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Aged, 80 and over, Purpura, Thrombocytopenic, Idiopathic drug therapy, Aminopyridines therapeutic use, Aminopyridines adverse effects, Morpholines therapeutic use, Morpholines adverse effects, Pyridines therapeutic use, Pyridines adverse effects
- Abstract
Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second-line treatment for ITP. Real-world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region of Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed ITP 6.8%; persistent 13.6%; chronic 79.5%; median four prior treatments) after ≥ 4 weeks of fostamatinib therapy. The median PLT at the initiation of fostamatinib was 15 × 10
9 /L. Common reasons for starting fostamatinib were refractoriness or intolerance to prior therapy, oral medication preference, history of thrombosis and cardiovascular risk. Dosing was individualized based on efficacy and tolerance. After 2 weeks, global response rate was 56.8% (response and complete response). Response rates were 70.5%, 62.5% and 64% at 4 weeks, 12 weeks and at the end of the study respectively. Adverse events were mild, and no patients discontinued as a result. This real-world study demonstrated a response rate similar to fostamatinib as seen in the pivotal clinical trials while including newly diagnosed patients and allowing for individualized dosing., (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
4. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
- Author
-
González-López TJ, Sánchez-González B, Jarque I, Bernat S, Fernández-Fuertes F, Caparrós I, Soto I, Fernández-Rodríguez A, Bolaños E, Pérez-Rus G, Pascual C, Hernández-Rivas JA, López-Ansoar E, Gómez-Nuñez M, Martínez-Robles V, Olivera P, Yera Cobo M, Peñarrubia MJ, Fernández-Miñano C, de Cabo E, Martínez Badas MP, Perdomo G, and García-Frade LJ
- Subjects
- Age Factors, Aged, Aged, 80 and over, Benzoates administration & dosage, Benzoates adverse effects, Biomarkers, Combined Modality Therapy, Comorbidity, Drug Therapy, Combination, Female, Humans, Hydrazines administration & dosage, Hydrazines adverse effects, Male, Prognosis, Purpura, Thrombocytopenic, Idiopathic blood, Purpura, Thrombocytopenic, Idiopathic diagnosis, Pyrazoles administration & dosage, Pyrazoles adverse effects, Retrospective Studies, Treatment Outcome, Benzoates therapeutic use, Hydrazines therapeutic use, Purpura, Thrombocytopenic, Idiopathic drug therapy, Pyrazoles therapeutic use
- Abstract
Background: Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65-year-old population., Methods: A total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated., Results: Median age of our cohort was 76 (interquartile range, IQR, 70-81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8-21) days. Median time on response was 320 (IQR, 147-526) days. Sixty-three adverse events (AEs), mainly grade 1-2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self-limited pulmonary embolisms in secondary ITP were the only thrombotic events observed., Conclusion: Eltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD-ITP were poor. A relatively high number of deaths were observed., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
5. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
- Author
-
Mingot-Castellano ME, Caparrós IS, Fernández F, Perera-Alvarez MDM, Jimenez-Bárcenas R, Casaus García A, González-Silva M, Yera-Cobo M, Nieto-Hernandez MM, Rodríguez-Fernandez MJ, and Díaz-Canales D
- Subjects
- Adult, Aged, Benzoates therapeutic use, Disease Management, Female, Humans, Hydrazines therapeutic use, Male, Middle Aged, Pyrazoles therapeutic use, Receptors, Fc therapeutic use, Receptors, Thrombopoietin agonists, Recombinant Fusion Proteins therapeutic use, Retrospective Studies, Treatment Outcome, Purpura, Thrombocytopenic, Idiopathic drug therapy, Thrombopoietin therapeutic use
- Abstract
: Thrombopoietin receptor agonist (TPO-RAs) have demonstrated good efficacy and tolerance in clinical trials in refractory chronic primary immune thrombocytopenia (ITP) or chronic ITP with contraindication for splenectomy. No head-to-head study is available, and differences in trials design do not allow comparisons. Information on the use of TPO-RAs in nonchronic ITP is scant. We described our experience with TPO-RAs in ITP (chronic, persistent and newly diagnosed ITP) in routine clinical practice. Retrospective series of 100 adult ITP patients was analysed; 41 treated with eltrombopag, 37 with romiplostim and 22 with both. Response-related and safety variables were evaluated. With a median follow-up of 86.5 weeks (interquartile range, 34.3-128 weeks), no differences were found in response rate, time to response, stability of response or response duration based on the type of TPO-RA used. Of all, 25% of patients with newly diagnosed or persistent ITP and 7.2% with chronic responded and maintained their response when TPO-RAs were stopped. Regarding safety, two developed bone marrow fibrosis grade 3, with loss of response to both drugs. Incidence of vascular events was 7%. Both TPO-RAs may be useful in all types of ITP, not only chronic but also persistent and newly diagnosed. Similar results were noted in efficacy and safety variables for both drugs.
- Published
- 2018
- Full Text
- View/download PDF
6. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
- Author
-
González-López TJ, Alvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Pérez-Rus G, Hernández-Rivas JA, Bernat S, Bastida JM, Martínez-Badas MP, Martínez-Robles V, Soto I, Olivera P, Bolaños E, Alonso R, Entrena L, Gómez-Nuñez M, Alonso A, Yera Cobo M, Caparrós I, Tenorio M, Arrieta-Cerdán E, Lopez-Ansoar E, García-Frade J, and González-Porras JR
- Subjects
- Adult, Aged, Autoimmune Diseases complications, Benzoates administration & dosage, Benzoates adverse effects, Drug Administration Schedule, Female, Humans, Hydrazines administration & dosage, Hydrazines adverse effects, Lymphoproliferative Disorders complications, Male, Middle Aged, Platelet Count, Purpura, Thrombocytopenic, Idiopathic blood, Purpura, Thrombocytopenic, Idiopathic etiology, Pyrazoles administration & dosage, Pyrazoles adverse effects, Receptors, Thrombopoietin agonists, Retrospective Studies, Virus Diseases complications, Benzoates therapeutic use, Hydrazines therapeutic use, Purpura, Thrombocytopenic, Idiopathic drug therapy, Pyrazoles therapeutic use
- Abstract
Eltrombopag is a second-line treatment in primary immune thrombocytopenia (ITP). However, its role in secondary ITP is unknown. We evaluated the efficacy and safety of eltrombopag in secondary ITP in daily clinical practice. Eighty-seven secondary ITP patients (46 with ITP secondary to autoimmune syndromes, 23 with ITP secondary to a neoplastic disease subtype: lymphoproliferative disorders [LPDs] and 18 with ITP secondary to viral infections) who had been treated with eltrombopag were retrospectively evaluated. Forty-four patients (38%) had a platelet response, including 40 (35%) with complete responses. Median time to platelet response was 15 days (95% confidence interval, 7-28 days), and was longer in the LPD-ITP group. Platelet response rate was significantly lower in the LPD-ITP than in other groups. However, having achieved response, there were no significant differences between the durable response of the groups. Forty-three patients (49·4%) experienced adverse events (mainly grade 1-2), the commonest being hepatobiliary laboratory abnormalities. There were 10 deaths in this case series, all of which were related to pre-existing medical conditions. In routine clinical practice, eltrombopag is effective and well-tolerated in unselected patients with ITP secondary to both immune and infectious disorders. However, the response rate in LPD-ITP is low., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.